Zevra Therapeutics Announces Collaboration with RARE-X and the Sleep Consortium as Founding Member of New Sleep Data Initiative
March 17, 2023 07:30 ET
|
Zevra Therapeutics
New Patent Issued Covering Serdexmethylphenidate (SDX), the Sole Active Pharmaceutical Ingredient in KP1077, Zevra’s Product Candidate for the Treatment of Idiopathic Hypersomnia (IH) CELEBRATION,...
Zevra Therapeutics Files Definitive Proxy Statement and Mails Letter to Shareholders
March 15, 2023 07:26 ET
|
Zevra Therapeutics
Urges Shareholders to Vote "FOR" All Zevra Director Nominees on the WHITE Proxy Card CELEBRATION, Fla., March 15, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NasdaqGS: ZVRA) (“Zevra” or the...
Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Updates
March 07, 2023 07:00 ET
|
Zevra Therapeutics
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, March 7, 2023, 8:30 a.m. ET Newly rebranded Zevra Therapeutics well positioned to become a commercially focused...
Zevra Therapeutics to Present at 35th Annual Roth Conference
March 06, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., March 06, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today...
Zevra Therapeutics Begins Trading as ZVRA
March 01, 2023 07:43 ET
|
Zevra Therapeutics
Company’s common stock will begin trading on the Nasdaq Global Select Market under the new ticker symbol “ZVRA” starting today, March 1, 2023 New Company name, Zevra, is Greek for zebra, the...
Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD)
February 28, 2023 08:00 ET
|
Zevra Therapeutics
CELEBRATION, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today...
Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy
February 27, 2023 16:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly known as KemPharm, Inc.), today announced it has filed its...
Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results
February 27, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced...
Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023
February 24, 2023 07:30 ET
|
Zevra Therapeutics
Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce long-term progression of Niemann-Pick Disease Type C (NPC) CELEBRATION, Fla.,...
Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023
February 23, 2023 07:30 ET
|
KemPharm
CELEBRATION, Fla., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced...